Fondation Mérieux, Direction Médicale et Scientifique, Lyon, France.
Département de Biologie, Ecole Normale Supérieure de Lyon, Lyon, France.
PLoS One. 2021 Mar 18;16(3):e0248707. doi: 10.1371/journal.pone.0248707. eCollection 2021.
Tuberculosis (TB) is the leading infectious cause of death in the world. Multi-drug resistant TB (MDR-TB) is a major public health problem as treatment is long, costly, and associated to poor outcomes. Here, we report epidemiological data on the prevalence of drug-resistant TB in Haiti.
This cross-sectional prevalence study was conducted in five health centers across Haiti. Adult, microbiologically confirmed pulmonary TB patients were included. Molecular genotyping (rpoB gene sequencing and spoligotyping) and phenotypic drug susceptibility testing were used to characterize rifampin-resistant MTB isolates detected by Xpert MTB/RIF.
Between April 2016 and February 2018, 2,777 patients were diagnosed with pulmonary TB by Xpert MTB/RIF screening and positive MTB cultures. A total of 74 (2.7%) patients were infected by a drug-resistant (DR-TB) M. tuberculosis strain. Overall HIV prevalence was 14.1%. Patients with HIV infection were at a significantly higher risk for infection with DR-TB strains compared to pan-susceptible strains (28.4% vs. 13.7%, adjusted odds ratio 2.6, 95% confidence interval 1.5-4.4, P = 0.001). Among the detected DR-TB strains, T1 (29.3%), LAM9 (13.3%), and H3 (10.7%) were the most frequent clades. In comparison with previous spoligotypes studies with data collected in 2000-2002 and in 2008-2009 on both sensitive and resistant strains of TB in Haiti, we observed a significant increase in the prevalence of the drug-resistant MTB Spoligo-International-Types (SIT) 137 (X2 clade: 8.1% vs. 0.3% in 2000-02 and 0.9% in 2008-09, p<0.001), 5 (T1 clade: 6.8% vs 1.9 in 2000-02 and 1.7% in 2008-09, P = 0.034) and 455 (T1 clade: 5.4% vs 1.6% and 1.1%, P = 0.029). Newly detected spoligotypes (SIT 6, 7, 373, 909 and 1624) were also recorded.
This study describes the genotypic and phenotypic characteristics of DR-TB strains circulating in Haiti from April 2016 to February 2018. Newly detected MTB clades harboring multi-drug resistance patterns among the Haitian population as well as the higher risk of MDR-TB infection in HIV-positive people highlights the epidemiological relevance of these surveillance data. The importance of detecting RIF-resistant patients, as proxy for MDR-TB in peripheral sites via molecular techniques, is particularly important to provide adequate patient case management, prevent the transmission of resistant strains in the community and to contribute to the surveillance of resistant strains.
结核病(TB)是世界上导致死亡的首要传染病。耐多药结核病(MDR-TB)是一个主要的公共卫生问题,因为其治疗时间长、费用高,且治疗结果不佳。在此,我们报告海地耐药结核病的流行情况。
本横断面患病率研究在海地的五个卫生中心进行。纳入了经微生物学确诊的肺结核成年患者。使用分子基因分型(rpoB 基因测序和 spoligotyping)和表型药敏试验来鉴定 Xpert MTB/RIF 检测到的利福平耐药 MTB 分离株。
2016 年 4 月至 2018 年 2 月,共有 2777 名患者通过 Xpert MTB/RIF 筛查和 MTB 阳性培养被诊断为肺结核。共有 74 名(2.7%)患者感染了耐药(DR-TB)结核分枝杆菌菌株。总 HIV 感染率为 14.1%。与敏感株相比,感染 HIV 的患者感染 DR-TB 株的风险显著更高(28.4%比 13.7%,调整后的比值比 2.6,95%置信区间 1.5-4.4,P=0.001)。在所检测的 DR-TB 菌株中,T1(29.3%)、LAM9(13.3%)和 H3(10.7%)是最常见的分枝杆菌。与之前在 2000-2002 年和 2008-2009 年在海地对敏感和耐药结核菌株进行的 spoligotype 研究数据相比,我们观察到耐多药 MTB Spoligo-International-Types(SIT)137(X2 分枝杆菌:8.1%比 2000-02 年的 0.3%和 2008-09 年的 0.9%,P<0.001)、5(T1 分枝杆菌:6.8%比 2000-02 年的 1.9%和 2008-09 年的 1.7%,P=0.034)和 455(T1 分枝杆菌:5.4%比 2000-02 年的 1.6%和 1.1%,P=0.029)的流行率显著增加。还记录了新发现的 spoligotype(SIT 6、7、373、909 和 1624)。
本研究描述了 2016 年 4 月至 2018 年 2 月期间在海地流行的 DR-TB 菌株的基因和表型特征。海地人群中新型耐多药结核分枝杆菌分枝杆菌的出现以及 HIV 阳性人群中 MDR-TB 感染的高风险,突显了这些监测数据的流行病学意义。通过分子技术在周边地区检测利福平耐药患者(作为 MDR-TB 的替代指标),对于提供适当的患者病例管理、预防社区中耐药菌株的传播以及为耐药菌株监测做出贡献至关重要。